Amgen Yönetim

Yönetim kriter kontrolleri 3/4

Amgen CEO'su Bob Bradway, May2010 tarihinde atandı, in görev süresi 14.5 yıldır. in toplam yıllık tazminatı $ 22.64M olup, şirket hissesi ve opsiyonları dahil olmak üzere 7.9% maaş ve 92.1% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.12% ine doğrudan sahiptir ve bu hisseler R$ 1.07B değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 4.8 yıl ve 7.9 yıldır.

Anahtar bilgiler

Bob Bradway

İcra Kurulu Başkanı

US$22.6m

Toplam tazminat

CEO maaş yüzdesi	7.9%
CEO görev süresi	14.5yrs
CEO sahipliği	0.1%
Yönetim ortalama görev süresi	4.8yrs
Yönetim Kurulu ortalama görev süresi	7.9yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Bob Bradway'un ücretlendirmesi Amgen'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	US$4b
Jun 30 2024	n/a	n/a	US$3b
Mar 31 2024	n/a	n/a	US$4b
Dec 31 2023	US$23m	US$2m	US$7b
Sep 30 2023	n/a	n/a	US$8b
Jun 30 2023	n/a	n/a	US$8b
Mar 31 2023	n/a	n/a	US$8b
Dec 31 2022	US$21m	US$2m	US$7b
Sep 30 2022	n/a	n/a	US$7b
Jun 30 2022	n/a	n/a	US$7b
Mar 31 2022	n/a	n/a	US$6b
Dec 31 2021	US$22m	US$2m	US$6b
Sep 30 2021	n/a	n/a	US$6b
Jun 30 2021	n/a	n/a	US$6b
Mar 31 2021	n/a	n/a	US$7b
Dec 31 2020	US$20m	US$2m	US$7b
Sep 30 2020	n/a	n/a	US$7b
Jun 30 2020	n/a	n/a	US$7b
Mar 31 2020	n/a	n/a	US$8b
Dec 31 2019	US$20m	US$2m	US$8b
Sep 30 2019	n/a	n/a	US$8b
Jun 30 2019	n/a	n/a	US$8b
Mar 31 2019	n/a	n/a	US$8b
Dec 31 2018	US$19m	US$2m	US$8b
Sep 30 2018	n/a	n/a	US$2b
Jun 30 2018	n/a	n/a	US$2b
Mar 31 2018	n/a	n/a	US$2b
Dec 31 2017	US$17m	US$2m	US$2b

Tazminat ve Piyasa: Bob 'nin toplam tazminatı ($USD 22.64M ), BR pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 5.75M ).

Tazminat ve Kazançlar: Bob 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Bob Bradway (61 yo)

14.5yrs

Görev süresi

US$22,643,650

Tazminat

Mr. Robert A. Bradway, also known as Bob, has been the Chief Executive Officer of Amgen Inc. since May 23, 2012 and has been its President since May 2010. Mr. Bradway is responsible for the Amgen's global...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Robert Bradway	Chairman	14.5yrs	US$22.64m	0.12% R$ 1.1b
Peter Griffith	Executive VP & CFO	4.8yrs	US$7.57m	0.0046% R$ 42.4m
Esteban Santos	Executive Vice President of Operations	8.3yrs	US$7.21m	0.011% R$ 105.0m
David Reese	Executive VP & CTO	less than a year	US$7.90m	0.0094% R$ 86.3m
Murdo Gordon	Executive Vice President of Global Commercial Operations	6.2yrs	US$8.24m	0.0075% R$ 68.6m
Matthew Busch	Chief Accounting Officer & VP of Finance	1.3yrs	Veri yok	0.00062% R$ 5.7m
James Bradner	Executive VP of Research & Development and Chief Scientific Officer	less than a year	Veri yok	Veri yok
Scott Skellenger	Senior VP & Chief Information Officer	no data	Veri yok	Veri yok
Justin Claeys	Vice President of Investor Relations	no data	Veri yok	Veri yok
Jonathan Graham	Executive VP	9.3yrs	US$7.24m	0.0046% R$ 42.7m
Nancy Grygiel	Senior VP of Worldwide Compliance & Business Ethics and Chief Compliance Officer	4.8yrs	Veri yok	0.0013% R$ 12.0m
Kave Niksefat	Senior Vice President of Global Marketing & Access	less than a year	Veri yok	Veri yok

4.8yrs

Ortalama Görev Süresi

57yo

Ortalama Yaş

Deneyimli Yönetim: AMGN34 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4.8 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Robert Bradway	Chairman	13.1yrs	US$22.64m	0.12% R$ 1.1b
Robert Eckert	Lead Independent Director	11.9yrs	US$419.92k	0.0013% R$ 12.0m
David Baltimore	Co-Chair of Scientific Advisory Board	no data	US$292.01k	Veri yok
Charles Sigal	Co-Chair of the Scientific Advisory Board	no data	Veri yok	Veri yok
Amy Miles	Independent Director	4.3yrs	US$359.92k	0.000080% R$ 735.3k
Charles Holley	Independent Director	7.8yrs	US$369.92k	0.00023% R$ 2.1m
Greg Garland	Independent Director	11.1yrs	US$379.92k	0.0023% R$ 21.1m
Ellen Kullman	Independent Director	8.1yrs	US$360.29k	0.000080% R$ 735.3k
Brian Druker	Independent Director	6.5yrs	US$359.92k	0.00015% R$ 1.4m
Tyler Jacks	Independent Director	12.5yrs	US$339.92k	0.00051% R$ 4.7m
Wanda Austin	Independent Director	6.9yrs	US$359.92k	0.0012% R$ 11.2m
S. Ishrak	Independent Director	3.3yrs	US$366.47k	0.00017% R$ 1.6m

7.9yrs

Ortalama Görev Süresi

68yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: AMGN34 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 7.9 yıldır).

Amgen Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Howard Chang Joins Amgen as Senior Vice President of Research and Chief Scientific Officer, Effective December 16, 2024

Amgen Inc. Appoints Anumita Tripathi as Director of Corporate Affairs for Amgen India

Amgen Inc., Annual General Meeting, May 31, 2024

Amgen Inc. Announces Executive Changes

Amgen Inc. Announces Management Changes

Recent updates

Howard Chang Joins Amgen as Senior Vice President of Research and Chief Scientific Officer, Effective December 16, 2024

Amgen and AstraZeneca Announce Positive Top-Line Results from the Phase 3 WayPOINT Trial in Patients with Chronic Rhinosinusitis with Nasal Polyps

Amgen Inc. Provides Earnings Guidance for the Full Year 2024

Amgen Inc. Announces Dividend for the Fourth Quarter of 2024, Payable on December 9, 2024

Amgen Inc. to Report Q3, 2024 Results on Oct 30, 2024

Amgen Announces Presents Positive Top-Line Results from the Phase 3 MINT Trial Evaluating the Efficacy and Safety of UPLIZNA

Amgen Inc. Appoints Anumita Tripathi as Director of Corporate Affairs for Amgen India

Amgen Announces Otezla®? (Apremilast) Now Available in the U.S. for Moderate to Severe Plaque Psoriasis

Amgen Inc. Provides Earnings Guidance for the Year Ending December 31, 2024

Amgen Inc. to Report Q2, 2024 Results on Aug 06, 2024

Amgen Inc. Announces U.S. Food and Drug Administration Approves Blincyto

Amgen Announces Positive Results for Phase 3 Registrational Trial Evaluating Uplizna® (Inebilizumab-Cdon) for Treatment of Immunoglobulin G4-Related Disease (Igg4-Rd)

FDA Approves Amgen's IMDELLTRA™? (Tarlatamab-Llle) for the Treatment of Adult Patients with Extensive-Stage Small Cell Lung Cancer

Amgen Inc. Provides Earnings Guidance for the Year Ending December 31, 2024

Amgen Inc. to Report Q1, 2024 Results on May 02, 2024

Amgen to Submits Marketing Authorization Application to the European Medicines Agency

Amgen Inc., Annual General Meeting, May 31, 2024

Amgen Presents New Research on Otezla (Apremilast) at AAD 2024

Amgen Announces 2024 Second Quarter Dividend, Payable on June 7,2024

Amgen Inc. Provides Earnings Guidance for the Year Ending December 31, 2024

Amgen Inc. to Report Q4, 2023 Results on Feb 06, 2024

Amgen Provides Regulatory Update on Status of LUMAKRAS (Sotorasib)

Amgen Inc. Announces Executive Changes

Amgen Presents New Data from Phase 2 Trial of Dazodalibep in Sjogren's Syndrome at ACR 2023

Amgen Inc. Presents New Data That Show Blood Pressure Decides for Results Treated with Krystexxa (PegLOTICase)

Amgen Inc. Provides Earnings Guidance for the Full Year 2023

Amgen Inc. to Report Q3, 2023 Results on Oct 31, 2023

Amgen Inc. Declares Dividend for the Fourth Quarter of 2023, Payable on December 8, 2023

Amgen Presents New LUMAKRAS (Sotorasib) Plus Vectibix (Panitumumab) Data in Patients with KRAS G12C-Mutated Metastatic Colorectal Cancer

Amgen Inc. to Present New Research from Oncolfolio and Pipeline At ESMO2023

Amgen Inc. (NasdaqGS:AMGN) completed the acquisition of Horizon Therapeutics Public Limited Company (NasdaqGS:HZNP).

Amgen Presents New Lumakras® (Sotorasib) Plus Chemotherapy Data in First-Line Kras G12c Nsclc At Wclc

Amgen and Horizon Therapeutics plc Resolve FTC Lawsuit, Clearing Path to Close Acquisition

Amgen and Horizon Therapeutics plc Resolve FTC Lawsuit, Clearing Path to Close Acquisition

Amgen Presents Phase 2 OLPASIRan Data at ESC 2023

Amgen Announces to Discuss Application for LUMAKRAS (Sotorasib) for Treatment of KRAS G12C-Positive NSCLC at FDA Advisory Committee Meeting

Amgen Inc. Announces Management Changes

Amgen Inc. Provides Earnings Guidance for the Year Ending December 31, 2023

Amgen Inc. to Report Q2, 2023 Results on Aug 03, 2023

Amgen Inc. Announces U.S. Food and Drug Administration Approves Supplemental Biologics License Application for BLINCYTO

Amgen Presents New Lumakras® (Sotorasib) Codebreak 200 CNS Data At Asco 2023

Amgen Presents New Scientific and Clinical Research Across its Diverse Oncology Portfolio and Pipeline at ASCO 2023

Amgen Presents New Research on Otezla® (Apremilast) in Psoriatic Arthritis At Eular 2023

Amgen Inc. Announces New Data from A Real-World Study of Nearly Half of Million Postmenopausal Women with Osteoporosis in the U.S. Medicare Program

AstraZeneca and Amgen Announce Approval of TEZSPIRE® (tezepelumab-ekko) in the US

Amgen Inc. to Report Q4, 2022 Results on Jan 31, 2023

Amgen Announces ECOG-ACRIN Cancer Research Group Results

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş